
Feb 25 (Reuters) - Adial Pharmaceuticals Inc ADIL.O:
ADIAL PHARMACEUTICALS RECEIVES POSITIVE RESPONSE FROM FDA MEETING REGARDING PROPOSED IN VITRO BRIDGING STRATEGY FOR AD04
ADIAL PHARMACEUTICALS- MOVES FORWARD WITH MANUFACTURING CLINICAL SUPPLIES FOR PHASE 3 PROGRAM IN 2025
Source text: ID:nGNX9ZpY9Q
Further company coverage: ADIL.O